PDF(Pubmed)
Abstract：
UNASSIGNED: Periorificial dermatitis (POD) is a common, chronic, inflammatory facial skin rash that presents as tiny papules and papulopustules with underlying eczematous-like patches, typically confined to the perioral, perinasal, and periorbital areas. There is currently no Food and Drug Administration (FDA)-indicated treatment for POD; however, broad-spectrum antibiotics are efficacious as a treatment option. Broad-spectrum antibiotics negatively impact gut flora and lead to antibiotic resistance. Narrow-spectrum tetracyclines, such as sarecycline, have a low potential for promoting bacterial resistance and gastrointestinal issues.
UNASSIGNED: We conducted a retrospective chart review in order to evaluate the efficacy of sarecycline in a cohort of patients diagnosed with POD that were treated with sarecycline.
UNASSIGNED: A review of medical records was completed using an electronic medical record. Inclusion criteria included males and females aged 18 to 95 with a diagnosis of POD, treated with sarecycline with a documented follow-up.
UNASSIGNED: Six patients met inclusion criteria, all of which had shown improvement with no reported side effects. Of the six patients, four were female and two were male and the patient ages ranged from 26 to 58 years old (mean=41 years). The course of therapy ranged from 30 to180 days (median=90 days).
UNASSIGNED: Based on the outcomes, there are many potential benefits to treatment of POD with sarecycline over the alternative tetracycline-class antibiotics. There is a need for more large-scale clinical studies evaluating treatment options for POD. Based on the efficacy and tolerability of sarecycline in large- scale acne studies, sarecycline may be an appropriate novel treatment option for POD and should be explored further.
UNASSIGNED: We conducted a retrospective chart review in order to evaluate the efficacy of sarecycline in a cohort of patients diagnosed with POD that were treated with sarecycline.
UNASSIGNED: A review of medical records was completed using an electronic medical record. Inclusion criteria included males and females aged 18 to 95 with a diagnosis of POD, treated with sarecycline with a documented follow-up.
UNASSIGNED: Six patients met inclusion criteria, all of which had shown improvement with no reported side effects. Of the six patients, four were female and two were male and the patient ages ranged from 26 to 58 years old (mean=41 years). The course of therapy ranged from 30 to180 days (median=90 days).
UNASSIGNED: Based on the outcomes, there are many potential benefits to treatment of POD with sarecycline over the alternative tetracycline-class antibiotics. There is a need for more large-scale clinical studies evaluating treatment options for POD. Based on the efficacy and tolerability of sarecycline in large- scale acne studies, sarecycline may be an appropriate novel treatment option for POD and should be explored further.
摘要：
■围手术期皮炎（POD）是一种常见的，慢性，炎性面部皮肤皮疹，表现为微小丘疹和丘疹脓疱，带有潜在的湿疹样斑块，通常局限于口周，经鼻,和眶周区域。目前尚无食品和药物管理局（FDA）指定的POD治疗方法；但是，广谱抗生素作为一种有效的治疗选择。广谱抗生素对肠道菌群产生负面影响并导致抗生素耐药性。窄谱四环素,比如sarreccine,具有促进细菌耐药性和胃肠道问题的低潜力。
■我们进行了回顾性图表回顾，以评估在一组被诊断为POD的患者中使用sarecycine的疗效。
■使用电子病历完成病历审查。纳入标准包括18至95岁的男性和女性，诊断为POD，用sareccine治疗，并进行了有记录的随访。
■6名患者符合纳入标准，所有这些都显示出改善，没有报道的副作用。六个病人中,4例为女性,2例为男性,患者年龄为26~58岁(平均41岁).疗程为30至180天（中位数=90天）。
■根据结果，与替代的四环素类抗生素相比,使用sareccine治疗POD有许多潜在的益处.需要更大规模的临床研究来评估POD的治疗选择。基于在大规模痤疮研究中的功效和耐受性，sarecycline可能是POD的一种合适的新型治疗选择，应进一步探索。
■我们进行了回顾性图表回顾，以评估在一组被诊断为POD的患者中使用sarecycine的疗效。
■使用电子病历完成病历审查。纳入标准包括18至95岁的男性和女性，诊断为POD，用sareccine治疗，并进行了有记录的随访。
■6名患者符合纳入标准，所有这些都显示出改善，没有报道的副作用。六个病人中,4例为女性,2例为男性,患者年龄为26~58岁(平均41岁).疗程为30至180天（中位数=90天）。
■根据结果，与替代的四环素类抗生素相比,使用sareccine治疗POD有许多潜在的益处.需要更大规模的临床研究来评估POD的治疗选择。基于在大规模痤疮研究中的功效和耐受性，sarecycline可能是POD的一种合适的新型治疗选择，应进一步探索。
